Pharmaceutical Sciences

Pharmaceutical Sciences Experts

Matthew Hanley

Scientific Director
Drugs similar to existing therapies
Thetis Pharmaceuticals LLC
United States of America


Dr. Hanley is a biomedical scientist with a background in molecular genetics, genomics, and cancer biology. His doctorate was completed under the mentorship of Dr. Daniel W. Rosenberg at UConn Health, where his research focused on the etiology and prevention of colorectal cancer. His primary work explored the role of folate and other methyl donor nutrients in colonic neoplasia, and examined the effects of dietary methyl donor restriction on tumorigenesis in the ApcΔ14/+ mouse model of familial adenomatous polyposis. In addition, he led projects characterizing DNA methylation defects in human aberrant crypt foci, the earliest precursors to colorectal cancer, and utilized metabolomic profiling to identify novel targets for CRC prevention and treatment. Prior to his PhD, he received a BS in Biology from Union College.

Research Interest

Novel small molecule drugs to treat inflammatory bowel disease (IBD) based on a unique paradigm of resolving inflammation

Global Experts from United States of America

Global Experts in Subject

Share This Profile